We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosis

News   May 24, 2018 | Original story from University of Texas Health

 
Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosis

Working on a promising treatment for facial tumors tied to tuberous sclerosis complex, from the left, are Adelaide Hebert, M.D.; John Slopis, M.D.; Mary Kay Koenig, M.D.; Joshua Samuels, M.D., M.P.H.; and Hope Northrup, M.D. All are from McGovern Medical School at UTHealth in Houston with the exception of Slopis, who is with The University of Texas MD Anderson Cancer Center. Credit: Maricruz Kwon, UTHealth

 
 
 

RELATED ARTICLES

Protein Switches Sides in Leukemia

News

Researchers have discovered that an epigenetic protein called EZH2 delays the development of acute myeloid leukemia (AML) but then switches sides once the disease is established to help maintain tumor growth.

READ MORE

Device Would Allow TB Dosing to Switch From Daily to Monthly

News

A drug delivery device is under development, which works by slowly releasing antibiotics directly into the patient's stomach. This would allow patients to switch from daily to monthly doses, reducing the burden of tuberculosis treatment.

READ MORE

From Mirror-image Biology to Enhanced Therapeutic Proteins

News

Biomolecules are being synthesized in their mirror-image form, as part of a bigger long-term goal: to create simple, artificial biological systems in mirror-image form that correspond to those in nature but do not interact with the environment.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE